Celltrion Healthcare passes $1 billion in bio exportsCelltrion Healthcare became the first Korean biopharmaceutical firm to pass $1 billion in exports.
On Thursday, its performance was recognized by the Korea International Trade Association, which awarded it the “$1 billion Export Tower.”
The company explained that its three biosimilars - Remsima, Truxima and Herzuma - were seeing sales rapidly increase in global markets. Celltrion Healthcare made up around 20 percent of Korea’s entire pharmaceutical exports of 4.67 billion won last year.
“Remsima SC authorized for sale in Europe last month is undergoing preparations to launch sales - with our lineup of globally sold products expanded to four next year, we’ll ramp up efforts to increase exports for the next $2 billion export threshold,” said Celltrion Healthcare CEO Kim Hyoung-ki.
By Song Kyoung-son